The world market for cancer therapeutics is growing at a brisk double-digit pace, with revenues surpassing $40 billion this year. This study looks at each therapeutic approach in turn, reporting and forecasting revenues from 2002 through 2009. Market share by leading competitor in each therapy type is estimated for the year 2004. Therapy types considered, include:
- Hormone Therapy
- Radiation Therapy
- Immunotherapy and Biotherapy, and
- Adjunctive Therapies
The study focuses on current and emerging markets, products in development, and trends affecting the cancer treatment market. Demographic and epidemiological data are presented for the major cancer types, therapies in development are reviewed by development stage and earliest possible approval date, and profiles of the leading and significant competitors are included for reference.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertain to the world market at the manufacturers’ level. The base year for data was 2004. Historical data was provided for the years 2002 and 2003, with forecast data provided for 2005 through 2009. Compound annual growth rates (CAGRs) are provided for the 2002-2004, 2004-2009 and 2002-2009 periods for each industry segment covered. Competitive analysis is provided for the year 2004. The forecasted market analysis for 2005-2009 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.